Viridian Therapeutics (VRDN) closed at $30.86 on November 10, 2026, up 2.2% from the previous close, on volume of 2,528,190 shares (30-day average 2,495,169).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Seagull With Call Spread | 18-Dec-2626 P : 35 C : 40 C | 726 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 5:50 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Cormedix (CRMD)
TipRanks (Mon, 9-Nov 11:10 AM ET)
Viridian Reports Positive Phase 1 Results for VRDN-008
TipRanks (Mon, 9-Nov 7:58 AM ET)
Business Wire (Mon, 9-Nov 7:01 AM ET)
Business Wire (Fri, 6-Nov 4:01 PM ET)
TipRanks (Fri, 6-Nov 8:50 AM ET)
VRDN highlights $24.7M Lumvoa launch quarter as multiple 2026–2027 milestones line up
Market Chameleon (Wed, 4-Nov 2:53 AM ET)
Business Wire (Wed, 4-Nov 7:01 AM ET)
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Business Wire (Tue, 20-Oct 4:00 PM ET)
Market Chameleon (Tue, 5-May 6:32 AM ET)
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.
As of November 11, 2026, VRDN stock price climbed to $31.58 with 1,037,264 million shares trading.
VRDN has a beta of -0.81, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.02 to the broad based SPY ETF.
VRDN has a market cap of $3.59 billion. This is considered a Mid Cap stock.
Last quarter Viridian Therapeutics reported $25,752 in Revenue and -$.81 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.21.
In the last 3 years, VRDN traded as high as $34.29 and as low as $9.90.
The top ETF exchange traded funds that VRDN belongs to (by Net Assets): IWM, XBI, VTI, VXF, IWN.
VRDN has outperformed the market in the last year with a price return of +14.2% while the SPY ETF gained +12.8%. VRDN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +36.9% and +31.1%, respectively, while the SPY returned -1.3% and -1.1%, respectively.
VRDN support price is $29.79 and resistance is $31.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.
